Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 25741 | 273 | 34.3 | 50% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 1 | 4 | ECONOMICS//EDUCATION & EDUCATIONAL RESEARCH//PSYCHOL | 3876184 |
| 320 | 3 | AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION//MEDICATION ERRORS//AMERICAN JOURNAL OF HOSPITAL PHARMACY | 39312 |
| 1464 | 2 | FOOD AND DRUG LAW JOURNAL//CONFLICT OF INTEREST//ORPHAN DRUGS | 7747 |
| 25741 | 1 | ANTIBACTERIAL DRUG DEVELOPMENT//INFECT GLOBAL MED DEV//ANTIBIOTIC INNOVATION | 273 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | ANTIBACTERIAL DRUG DEVELOPMENT | authKW | 251663 | 1% | 75% | 3 |
| 2 | INFECT GLOBAL MED DEV | address | 223702 | 1% | 100% | 2 |
| 3 | ANTIBIOTIC INNOVATION | authKW | 149133 | 1% | 67% | 2 |
| 4 | ACT ANTIBIOT ISTANCE | address | 111851 | 0% | 100% | 1 |
| 5 | ADVANCE MARKET COMMITMENT | authKW | 111851 | 0% | 100% | 1 |
| 6 | AFRICAN TRYPANOSOMOSIS HUMAN | authKW | 111851 | 0% | 100% | 1 |
| 7 | AGREEMENT ON TRADE RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS | authKW | 111851 | 0% | 100% | 1 |
| 8 | ANTI BIOTICS | authKW | 111851 | 0% | 100% | 1 |
| 9 | ANTIBIOTIC SUBSTITUTION | authKW | 111851 | 0% | 100% | 1 |
| 10 | ANTIINFECTIVE DRUG DISCOVERY | authKW | 111851 | 0% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Medical Ethics | 8740 | 11% | 0% | 30 |
| 2 | Ethics | 3336 | 12% | 0% | 32 |
| 3 | Infectious Diseases | 1387 | 22% | 0% | 59 |
| 4 | Microbiology | 674 | 22% | 0% | 59 |
| 5 | Social Sciences, Biomedical | 576 | 6% | 0% | 17 |
| 6 | Health Policy & Services | 509 | 7% | 0% | 20 |
| 7 | Social Issues | 492 | 4% | 0% | 12 |
| 8 | Pharmacology & Pharmacy | 481 | 26% | 0% | 71 |
| 9 | Health Care Sciences & Services | 319 | 8% | 0% | 21 |
| 10 | Medicine, Legal | 192 | 3% | 0% | 8 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | INFECT GLOBAL MED DEV | 223702 | 1% | 100% | 2 |
| 2 | ACT ANTIBIOT ISTANCE | 111851 | 0% | 100% | 1 |
| 3 | CHEM BIOL RADIOL NUCL COUNTERMEASU | 111851 | 0% | 100% | 1 |
| 4 | CIENCIAS JURID EMP ARIALES | 111851 | 0% | 100% | 1 |
| 5 | COMMUNICAT GOVT AFFAIRS | 111851 | 0% | 100% | 1 |
| 6 | DRUGS NEGLECTED DIS WORKING GRP | 111851 | 0% | 100% | 1 |
| 7 | GLOBAL HLTH HLTH SYST POLICY HSP IMPROVING USE | 111851 | 0% | 100% | 1 |
| 8 | IMMUNOINFLAMMAT INFECT DIS FRANCHISE | 111851 | 0% | 100% | 1 |
| 9 | INFECTIOUS DIS THER EUT AREA UNIT | 111851 | 0% | 100% | 1 |
| 10 | INSERM 1137 | 111851 | 0% | 100% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | PUBLIC HEALTH ETHICS | 30317 | 3% | 3% | 8 |
| 2 | HEALTH SECURITY | 13068 | 1% | 4% | 3 |
| 3 | KOREAN JOURNAL OF MEDICAL HISTORY | 12779 | 1% | 6% | 2 |
| 4 | DRUG RESISTANCE UPDATES | 8308 | 2% | 1% | 6 |
| 5 | JOURNAL OF LAW MEDICINE & ETHICS | 4962 | 3% | 1% | 8 |
| 6 | LANCET INFECTIOUS DISEASES | 3480 | 2% | 1% | 6 |
| 7 | UPSALA JOURNAL OF MEDICAL SCIENCES | 2710 | 2% | 0% | 5 |
| 8 | HEALTH ECONOMICS | 2142 | 2% | 0% | 6 |
| 9 | JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE | 1976 | 1% | 1% | 2 |
| 10 | CLINICAL INFECTIOUS DISEASES | 1946 | 5% | 0% | 15 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | LITTMANN, J , VIENS, AM , (2015) THE ETHICAL SIGNIFICANCE OF ANTIMICROBIAL RESISTANCE.PUBLIC HEALTH ETHICS. VOL. 8. ISSUE 3. P. 209 -224 | 20 | 47% | 6 |
| 2 | RENWICK, MJ , BROGAN, DM , MOSSIALOS, E , (2016) A SYSTEMATIC REVIEW AND CRITICAL ASSESSMENT OF INCENTIVE STRATEGIES FOR DISCOVERY AND DEVELOPMENT OF NOVEL ANTIBIOTICS.JOURNAL OF ANTIBIOTICS. VOL. 69. ISSUE 2. P. 73 -88 | 12 | 41% | 9 |
| 3 | LUEPKE, KH , SUDA, KJ , BOUCHER, H , RUSSO, RL , BONNEY, MW , HUNT, TD , MOHR, JF , (2017) PAST, PRESENT, AND FUTURE OF ANTIBACTERIAL ECONOMICS: INCREASING BACTERIAL RESISTANCE, LIMITED ANTIBIOTIC PIPELINE, AND SOCIETAL IMPLICATIONS.PHARMACOTHERAPY. VOL. 37. ISSUE 1. P. 71 -84 | 10 | 38% | 1 |
| 4 | SONDERHOLM, J , (2010) A THEORETICAL FLAW IN THE ADVANCE MARKET COMMITMENT IDEA.JOURNAL OF MEDICAL ETHICS. VOL. 36. ISSUE 6. P. 339-343 | 7 | 100% | 0 |
| 5 | SINHA, MS , KESSELHEIM, AS , (2016) REGULATORY INCENTIVES FOR ANTIBIOTIC DRUG DEVELOPMENT: A REVIEW OF RECENT PROPOSALS.BIOORGANIC & MEDICINAL CHEMISTRY. VOL. 24. ISSUE 24. P. 6446 -6451 | 11 | 55% | 0 |
| 6 | RIDLEY, DB , REGNIER, SA , (2016) THE COMMERCIAL MARKET FOR PRIORITY REVIEW VOUCHERS.HEALTH AFFAIRS. VOL. 35. ISSUE 5. P. 776 -783 | 7 | 58% | 2 |
| 7 | BILLINGTON, JK , (2016) A NEW PRODUCT DEVELOPMENT PARTNERSHIP MODEL FOR ANTIBIOTIC RESISTANCE.AMERICAN JOURNAL OF LAW & MEDICINE. VOL. 42. ISSUE 2-3. P. 487 -523 | 15 | 26% | 0 |
| 8 | ROBERTSON, AS , STEFANAKIS, R , JOSEPH, D , MOREE, M , (2012) THE IMPACT OF THE US PRIORITY REVIEW VOUCHER ON PRIVATE-SECTOR INVESTMENT IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT.PLOS NEGLECTED TROPICAL DISEASES. VOL. 6. ISSUE 8. P. - | 4 | 100% | 7 |
| 9 | REX, JH , OUTTERSON, K , (2016) ANTIBIOTIC REIMBURSEMENT IN A MODEL DELINKED FROM SALES: A BENCHMARK-BASED WORLDWIDE APPROACH.LANCET INFECTIOUS DISEASES. VOL. 16. ISSUE 4. P. 500 -505 | 7 | 47% | 2 |
| 10 | EICHBERG, MJ , (2015) PUBLIC FUNDING OF CLINICAL-STAGE ANTIBIOTIC DEVELOPMENT IN THE UNITED STATES AND EUROPEAN UNION.HEALTH SECURITY. VOL. 13. ISSUE 3. P. 156 -165 | 5 | 71% | 4 |
Classes with closest relation at Level 1 |